The estimated Net Worth of John Henry Stevens is at least $4.87 million dollars as of 26 June 2023. John Stevens owns over 316,455 units of Clene Nanomedicine stock worth over $4,873,242 and over the last 4 years John sold CLNN stock worth over $0.
Sign up
John Stevens CLNN stock SEC Form 4 insiders trading
John has made over 4 trades of the Clene Nanomedicine stock since 2022, according to the Form 4 filled with the SEC. Most recently John bought 316,455 units of CLNN stock worth $253,164 on 26 June 2023.
The largest trade John's ever made was buying 316,455 units of Clene Nanomedicine stock on 26 June 2023 worth over $253,164. On average, John trades about 49,114 units every 31 days since 2021. As of 26 June 2023 John still owns at least 800,204 units of Clene Nanomedicine stock.
You can see the complete history of John Stevens stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's John Stevens's mailing address?
John's mailing address filed with the SEC is 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY, UT, 84121.
Insiders trading at Clene Nanomedicine
Over the last 4 years, insiders at Clene Nanomedicine have traded over $1,293,164 worth of Clene Nanomedicine stock and bought 19,236,803 units worth $21,152,263 . The most active insiders traders include David J Matlin, Chidozie Ugwumba et Alison Mosca. On average, Clene Nanomedicine executives and independent directors trade stock every 26 days with the average trade being worth of $2,786,272. The most recent stock trade was executed by Robert Dee Etherington on 29 July 2024, trading 27,320 units of CLNN stock currently worth $81,960.
What does Clene Nanomedicine do?
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean surfaced nanotechnology (CSN) therapeutics. The company has a nanotechnology drug suspension; and engages in the development and commercialization of dietary supplements. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson's; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative diseases. The company's products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat disease-causing infections, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. Clene Inc. is headquartered in Salt Lake City, Utah.
What does Clene Nanomedicine's logo look like?
Complete history of John Stevens stock trades at Clene Nanomedicine
Clene Nanomedicine executives and stock owners
Clene Nanomedicine executives and other stock owners filed with the SEC include:
-
Robert Etherington,
CEO, Pres & Director -
Robert Etherington MBA,
CEO, Pres & Director -
Mark G. Mortenson,
Co-Founder & Chief Science Officer -
Dr. Robert Glanzman M.D.,
Chief Medical Officer -
Dr. Tae Heum Jeong,
Consultant -
Morgan R. Brown C.P.A., CPA, M.B.A., MBA,
Chief Financial Officer -
Mary Anne Mcneil,
Head of HR -
Michael Hotchkin,
Chief Devel. Officer -
Jerry Miraglia J.D.,
Gen. Counsel & Corp. Sec. -
Dr. Jeong Ted,
Chief Financial Officer -
Chidozie Ugwumba,
10% owner -
Matthew Kiernan,
-
Arjun Jj Desai,
-
Vallerie Mc Laughlin,
-
Shalom Jacobovitz,
-
Tae Heum Jeong,
Chief Finance Officer -
Alison Mosca,
-
David J Matlin,
-
Mark Mortenson,
Chief Science Officer -
Robert Glanzman,
Chief Medical Officer -
Fiona Costello,
-
Reed N Wilcox,
-
Robert Dee Etherington,
Chief Executive Officer -
John Henry Stevens,
-
Jonathon Gay,
-
Morgan R Brown,
Chief Financial Officer -
Resonance Llc General,
10% owner